Loading…
Loading…
EQUITY / NASDAQ · XNCM
Cadrenal Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.9951 USD · -7.8611%
Observed: Oct 1, 2026, 4:57 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 1.08 USD · Volume 21,803
62 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -3,340,400 USD | — | — |
| Net income | -3,322,565 USD | — | — |
| Cash and cash equivalents | 2,388,135 USD | — | — |
| Total liabilities | 1,497,257 USD | — | — |
| Total equity | 4,091,708 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 2,388,135 USD | — | — | 2,308,137 USD | 4,007,789 USD | 4,007,789 USD | 3,860,082 USD | — |
| Net incomeIncome statement | -3,322,565 USD | -5,819,105 USD | — | -2,496,540 USD | — | -13,237,362 USD | -2,685,705 USD | -10,198,372 USD |
| Operating profitIncome statement | -3,340,400 USD | -5,854,778 USD | — | -2,514,378 USD | — | -13,461,177 USD | -2,733,803 USD | -10,396,071 USD |
| Total assetsBalance sheet | 5,588,965 USD | — | — | 2,862,067 USD | 4,326,708 USD | 4,326,708 USD | 4,087,622 USD | — |
| Total equityBalance sheet | 4,091,708 USD | — | 1,797,116 USD | 1,797,115 USD | 2,738,726 USD | 2,738,726 USD | 2,734,947 USD | — |
| Total liabilitiesBalance sheet | 1,497,257 USD | — | — | 1,064,952 USD | 1,587,982 USD | 1,587,982 USD | 1,352,675 USD | — |
| Financing cash flowCash flow statement | — | 3,614,276 USD | — | 1,302,565 USD | — | 6,596,617 USD | — | 3,878,951 USD |
| Investing cash flowCash flow statement | — | 1,441 USD | — | — | — | -5,104 USD | — | -5,104 USD |
| Operating cash flowCash flow statement | — | -5,235,371 USD | — | -3,002,217 USD | — | -12,601,666 USD | — | -10,031,707 USD |
| Capital expendituresCash flow statement | — | — | — | — | — | 5,104 USD | — | 5,104 USD |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 05/07/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 11/10/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.